Trade Qiagen NV - QIA CFD

Add to favourite

37.945

0.77%

View detailed chart

0.130

Low: 37.425

High: 37.945

Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:30

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.130

Long position overnight fee

-0.022046%

Short position overnight fee

-0.000176%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

EUR

Margin

Stock exchange

Germany

Commission on trade

*Information provided by Capital.com

Qiagen NV ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats

Prev. Close*	37.655
Open*	37.655
1-Year Change*	-20.38%
Day's Range*	37.425 - 37.945
52 wk Range	34.74-51.18
Average Volume (10 days)	1.07M
Average Volume (3 months)	27.05M
Market Cap	9.21B
P/E Ratio	27.98
Shares Outstanding	228.18M
Revenue	1.95B
EPS	1.44
Dividend (Yield %)	N/A
Beta	0.42
Next Earnings Date	Feb 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 1, 2023	37.945	0.510	1.36%	37.435	37.955	37.405
Nov 30, 2023	37.655	0.420	1.13%	37.235	37.705	37.235
Nov 29, 2023	37.575	0.450	1.21%	37.125	37.765	37.055
Nov 28, 2023	37.065	0.190	0.52%	36.875	37.215	36.755
Nov 27, 2023	37.155	0.080	0.22%	37.075	37.655	37.075
Nov 24, 2023	37.245	-0.120	-0.32%	37.365	37.605	37.125
Nov 23, 2023	37.465	0.120	0.32%	37.345	37.535	37.035
Nov 22, 2023	37.525	0.570	1.54%	36.955	37.595	36.915
Nov 21, 2023	36.865	0.785	2.18%	36.080	36.895	36.080
Nov 20, 2023	36.110	-0.010	-0.03%	36.120	36.485	36.020
Nov 17, 2023	36.110	0.035	0.10%	36.075	36.595	36.075
Nov 16, 2023	36.270	0.220	0.61%	36.050	36.425	36.050
Nov 15, 2023	36.455	0.170	0.47%	36.285	36.855	36.010
Nov 14, 2023	36.365	0.615	1.72%	35.750	36.685	35.750
Nov 13, 2023	35.790	0.380	1.07%	35.410	35.840	35.310
Nov 10, 2023	35.140	-0.260	-0.73%	35.400	35.690	35.020
Nov 9, 2023	35.910	-0.110	-0.31%	36.020	36.395	35.840
Nov 8, 2023	36.305	0.020	0.06%	36.285	36.695	36.285
Nov 7, 2023	36.485	0.575	1.60%	35.910	36.655	35.890
Nov 6, 2023	36.260	-0.165	-0.45%	36.425	36.595	36.210

Qiagen NV Events

Time (UTC)	Country	Event
Tuesday, December 12, 2023
Time (UTC) 13:00	Country NL	Event Qiagen NV at Exane BNPP Diagnostics, Imaging & Life Sciences CEO Conference (Virtual) Qiagen NV at Exane BNPP Diagnostics, Imaging & Life Sciences CEO Conference (Virtual) Forecast - Previous -
Monday, February 5, 2024
Time (UTC) 21:05	Country NL	Event Q4 2023 Qiagen NV Earnings Release Q4 2023 Qiagen NV Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	2141.52	2251.66	1870.35	1526.42	1501.85
Revenue	2141.52	2251.66	1870.35	1526.42	1501.85
Cost of Revenue, Total	756.955	800.837	637.631	521.162	499.271
Gross Profit	1384.56	1450.82	1232.71	1005.26	1002.58
Total Operating Expense	1610.06	1621.57	1483.92	1547.76	1235.27
Selling/General/Admin. Expenses, Total	603.945	584.468	525.362	505.268	508.146
Research & Development	189.859	189.964	149.072	157.448	161.852
Depreciation / Amortization	14.531	18.542	20.811	29.973	39.032
Unusual Expense (Income)	44.768	27.762	151.039	333.91	26.966
Operating Income	531.46	630.084	386.431	-21.337	266.581
Interest Income (Expense), Net Non-Operating	-19.1	-5.122	-59.918	-43.696	-70.168
Other, Net	0.241	0.871	112.959	-12.743	29.324
Net Income Before Taxes	512.601	625.833	439.472	-77.776	225.737
Net Income After Taxes	423.211	512.599	359.188	-41.455	190.38
Minority Interest					0
Net Income Before Extra. Items	423.211	512.599	359.188	-41.455	190.38
Net Income	423.211	512.599	359.188	-41.455	190.38
Income Available to Common Excl. Extra. Items	423.211	512.599	359.188	-41.455	190.38
Income Available to Common Incl. Extra. Items	423.211	512.599	359.188	-41.455	190.38
Dilution Adjustment					0
Diluted Net Income	423.211	512.599	359.188	-41.455	190.38
Diluted Weighted Average Shares	230.136	232.034	234.214	226.777	233.456
Diluted EPS Excluding Extraordinary Items	1.83896	2.20915	1.53359	-0.1828	0.81549
Diluted Normalized EPS	1.99957	2.30715	2.00343	0.77427	0.9129
Total Extraordinary Items

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	494.857	485.398	497.984	499.631	515.512
Revenue	494.857	485.398	497.984	499.631	515.512
Cost of Revenue, Total	182.705	177.922	180.46	178.58	184.494
Gross Profit	312.152	307.476	317.524	321.051	331.018
Total Operating Expense	389.425	388.688	393.411	401.972	393.355
Selling/General/Admin. Expenses, Total	145.523	147.58	154.211	145.462	151.418
Research & Development	49.893	54.718	44.719	48.868	49.896
Depreciation / Amortization	2.702	2.657	5.969	2.846	2.799
Unusual Expense (Income)	8.602	5.811	8.052	26.216	4.748
Operating Income	105.432	96.71	104.573	97.659	122.157
Interest Income (Expense), Net Non-Operating	-3.054	11.954	1.387	-2.452	-6.521
Other, Net	-0.062	0.123	-0.123	0.511	-0.112
Net Income Before Taxes	102.316	108.787	105.837	95.718	115.524
Net Income After Taxes	80.786	85.035	88.844	82.394	96.661
Net Income Before Extra. Items	80.786	85.035	88.844	82.394	96.661
Net Income	80.786	85.035	88.844	82.394	96.661
Income Available to Common Excl. Extra. Items	80.786	85.035	88.844	82.394	96.661
Income Available to Common Incl. Extra. Items	80.786	85.035	88.844	82.394	96.661
Diluted Net Income	80.786	85.035	88.844	82.394	96.661
Diluted Weighted Average Shares	230.517	230.602	230.358	230.084	229.938
Diluted EPS Excluding Extraordinary Items	0.35046	0.36875	0.38568	0.3581	0.42038
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	0.37992	0.38845	0.41502	0.45618	0.43766

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	2393.95	2109.6	1624.41	1570.25	2155.06
Cash and Short Term Investments	1418.27	1065.3	715.233	753.233	1393.69
Cash	122.314	235.381	245.373	189.569	208.083
Short Term Investments	687.597	184.785	117.249	563.664	1185.6
Total Receivables, Net	434.068	469.663	486.605	484.608	422.091
Accounts Receivable - Trade, Net	333.518	376.213	389.058	385.117	351.612
Total Inventory	357.96	327.525	291.181	170.704	162.912
Prepaid Expenses	50.958	60.629	61.159	45.409	48.25
Other Current Assets, Total	132.7	186.484	70.227	116.294	128.122
Total Assets	6287.73	6146.95	5869.62	5235.62	5748.33
Property/Plant/Equipment, Total - Net	757.693	739.077	661.894	455.243	511.659
Property/Plant/Equipment, Total - Gross	1260.66	1371.49	1292.34	1154.37	1115.09
Accumulated Depreciation, Total	-502.967	-632.416	-630.443	-699.13	-603.43
Goodwill, Net	2352.57	2350.76	2364.03	2140.5	2108.54
Intangibles, Net	544.796	627.436	726.194	632.434	475.043
Other Long Term Assets, Total	215.225	294.676	488.995	356.488	437.434
Total Current Liabilities	974.523	1517.47	572.175	951.345	972.189
Accounts Payable	98.734	101.224	118.153	84.767	69.415
Accrued Expenses	215.702	219.936	220.755	332.151	209.748
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	389.552	847.626	42.539	285.244	503.177
Other Current Liabilities, Total	270.535	348.684	190.728	249.183	189.849
Total Liabilities	2821.12	3050.4	3071.78	2699.02	3113.36
Total Long Term Debt	1471.9	1094.14	1880.21	1421.11	1671.09
Long Term Debt	1471.9	1094.14	1880.21	1421.11	1671.09
Deferred Income Tax	17.5	37.591	39.216	23.442	63.411
Minority Interest
Other Liabilities, Total	357.203	401.199	580.179	303.13	406.672
Total Equity	3466.61	3096.55	2797.84	2536.59	2634.97
Common Stock	2.702	2.702	2.702	2.702	2.702
Additional Paid-In Capital	1868.02	1818.51	1834.17	1777.02	1742.19
Retained Earnings (Accumulated Deficit)	2160.17	1791.74	1323.09	1178.46	1379.62
Treasury Stock - Common	-160.188	-189.73	-118.301	-111.966	-178.903
Unrealized Gain (Loss)					0
Other Equity, Total	-404.091	-326.67	-243.822	-309.619	-310.644
Total Liabilities & Shareholders’ Equity	6287.73	6146.95	5869.62	5235.62	5748.33
Total Common Shares Outstanding	227.716	227.074	227.985	227.752	225.509
Long Term Investments	23.5	25.4	4.1	80.7	60.6
Note Receivable - Long Term
Cash & Equivalents	608.355	645.135	352.611

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1962.39	2311.43	2251.32	2393.95	2755.51
Cash and Short Term Investments	1015.78	1331.9	1287.34	1418.27	1886.98
Cash & Equivalents	579.935	609.549	359.18	730.669	1271.6
Short Term Investments	435.843	722.352	928.161	687.597	615.387
Total Receivables, Net	326.69	327.899	329.544	333.518	323.175
Accounts Receivable - Trade, Net	326.69	327.899	329.544	333.518	323.175
Total Inventory	399.207	391.989	380.824	357.96	323.472
Prepaid Expenses	220.715	259.639	253.609	284.208	221.882
Total Assets	5906.7	6347.27	6278.95	6287.73	6516.62
Property/Plant/Equipment, Total - Net	706.02	706.84	691.055	662.17	590.983
Property/Plant/Equipment, Total - Gross		1252.48	1222.98	1165.14	1075.87
Accumulated Depreciation, Total		-545.641	-531.924	-502.967	-484.887
Goodwill, Net	2434.47	2456.54	2454.08	2352.57	2299.26
Intangibles, Net	542.604	570.192	585.021	544.796	551.587
Long Term Investments		27.3	27.7	23.5	21
Other Long Term Assets, Total	261.217	274.97	269.778	310.748	298.273
Total Current Liabilities	524.371	978.45	890.244	974.523	1497.54
Accounts Payable	76.887	83.939	84.386	98.734	82.836
Accrued Expenses	346.876	325.962	341.615	417.237	487.562
Notes Payable/Short Term Debt		0	0	0	0
Current Port. of LT Debt/Capital Leases	100.608	500.149	393.243	389.552	866.04
Other Current Liabilities, Total		68.4	71	69	61.1
Total Liabilities	2213	2723.66	2717.78	2821.12	3188.86
Total Long Term Debt	1382.36	1387.94	1486.71	1471.9	1423.21
Long Term Debt	1382.36	1387.94	1486.71	1471.9	1423.21
Deferred Income Tax				17.5	9.387
Other Liabilities, Total	306.268	357.273	340.827	357.203	258.726
Total Equity	3693.7	3623.61	3561.18	3466.61	3327.76
Common Stock	2.702	2.702	2.702	2.702	2.702
Additional Paid-In Capital	1903.08	1890.02	1882.16	1868.02	1854.36
Retained Earnings (Accumulated Deficit)	2360.88	2283.06	2215.43	2160.17	2072.57
Treasury Stock - Common	-134.277	-134.277	-142.855	-160.188	-160.943
Other Equity, Total	-438.687	-417.902	-396.261	-404.091	-440.933
Total Liabilities & Shareholders’ Equity	5906.7	6347.27	6278.95	6287.73	6516.62
Total Common Shares Outstanding	228.182	228.182	228.035	227.716	227.7

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	423.211	512.599	359.188	-41.455	190.38
Cash From Operating Activities	715.264	639.001	457.806	330.843	359.496
Cash From Operating Activities	208.397	214.931	205.014	231.458	206.436
Deferred Taxes	-9.603	-5.288	-6.706	-55.362	-23.272
Non-Cash Items	125.14	46.771	-27.423	240.526	81.111
Cash Taxes Paid	98.565	102.083	42.572	41.474	29.317
Cash Interest Paid	23.208	21.588	25.351	29.721	25.902
Changes in Working Capital	-31.881	-130.012	-72.267	-44.324	-95.159
Cash From Investing Activities	-726.763	-202.426	-443.281	-222.278	-211.356
Capital Expenditures	-149.336	-206.534	-304.237	-274.884	-150.763
Other Investing Cash Flow Items, Total	-577.427	4.108	-139.044	52.606	-60.593
Cash From Financing Activities	-125.803	-150.366	-50.127	-639.08	360.408
Financing Cash Flow Items	-17.373	-16.953	-23.451	-61.279	-8.019
Issuance (Retirement) of Stock, Net	0.121	-92.068	8.876	62.362	-27.867
Issuance (Retirement) of Debt, Net	-108.551	-41.345	-35.552	-640.163	396.294
Foreign Exchange Effects	-12.545	-3.677	4.196	0.826	-7.183
Net Change in Cash	-149.847	282.532	-31.406	-529.689	501.365

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	85.035	423.211	334.367	251.973	155.312
Cash From Operating Activities	71.926	715.264	590.945	379.363	207.41
Cash From Operating Activities	52.061	208.397	153.725	103.408	52.998
Deferred Taxes	-4.341	-9.603	-40.196	-3.95	0.615
Non-Cash Items	13.323	125.14	95.413	47.519	21.86
Changes in Working Capital	-74.152	-31.881	47.636	-19.587	-23.375
Cash From Investing Activities	-433.847	-726.763	-602.237	-557.789	-306.252
Capital Expenditures	-38.409	-149.336	-102.745	-76.024	-38.415
Other Investing Cash Flow Items, Total	-395.438	-577.427	-499.492	-481.765	-267.837
Cash From Financing Activities	-9.828	-125.803	420.57	12.549	-10.658
Financing Cash Flow Items	-9.903	-17.373	49.011	12.443	-10.687
Issuance (Retirement) of Stock, Net	0.075	0.121	0.107	0.106	0.029
Issuance (Retirement) of Debt, Net		-108.551	371.452	0	0
Foreign Exchange Effects	0.26	-12.545	-18.197	-8.105	-0.501
Net Change in Cash	-371.489	-149.847	391.081	-173.982	-110.001

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
MFS Investment Management	Investment Advisor/Hedge Fund	8.7992	20078128	-102677	2023-06-30	LOW
The Vanguard Group, Inc.	Investment Advisor/Hedge Fund	3.722	8492990	141460	2023-06-30	LOW
Norges Bank Investment Management (NBIM)	Sovereign Wealth Fund	3.0334	6921770	10881	2023-05-09	LOW
Amundi Asset Management, SAS	Investment Advisor/Hedge Fund	1.9838	4526635	1663553	2023-06-30	LOW
Fidelity International	Investment Advisor	1.9505	4450800	1412750	2023-06-30	LOW
BlackRock Institutional Trust Company, N.A.	Investment Advisor	1.9066	4350561	-90657	2023-06-30	LOW
UBS Asset Management (Switzerland)	Investment Advisor	1.8754	4279398	765282	2022-12-19	LOW
Wellington Management Company, LLP	Investment Advisor/Hedge Fund	1.466	3345086	580634	2023-06-30	LOW
BlackRock Asset Management Deutschland AG	Investment Advisor	1.4559	3322170	25311	2023-09-30	LOW
Deka Investment GmbH	Investment Advisor/Hedge Fund	1.2493	2850742	388353	2023-06-30	LOW
Marshall Wace LLP	Investment Advisor/Hedge Fund	1.163	2653783	522140	2023-06-30	HIGH
Schroder Investment Management Ltd. (SIM)	Investment Advisor/Hedge Fund	1.1065	2524765	-14911	2023-08-31	LOW
State Street Global Advisors (US)	Investment Advisor/Hedge Fund	0.9641	2200010	-25442	2023-06-30	LOW
Legal & General Investment Management Ltd.	Investment Advisor/Hedge Fund	0.9014	2056848	327955	2023-06-30	LOW
Millennium Management LLC	Hedge Fund	0.857	1955605	1619566	2023-06-30	HIGH
Morgan Stanley & Co. LLC	Research Firm	0.8515	1943006	-12785	2023-06-30	MED
BofA Global Research (US)	Research Firm	0.8364	1908531	-182510	2023-06-30	LOW
HSBC Global Asset Management (UK) Limited	Investment Advisor/Hedge Fund	0.8349	1905156	-72184	2023-06-30	LOW
PRIMECAP Management Company	Investment Advisor	0.8182	1867017	-3540	2023-06-30
Nekton Capital Limited	Hedge Fund	0.7597	1733397	-49500	2023-06-30	HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Qiagen Company profile

About Qiagen NV

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Qiagen NV revenues increased 20% to $2.25B. Net income increased 43% to $512.6M. Revenues reflect Consumables and Related Revenues segment increase of 23% to $1.99B, Instrumentation segment increase of 4% to $265.3M, United States segment increase of 25% to $909.7M, Europe & Middle East & Afric segment increase of 19% to $814.4M. Net income benefited from Restructuring decrease of 81% to $27.8M (expense).

Equity composition

1/2017, Shares Consolidation (Factor: 0.96296).

Industry:

Biotechnology & Medical Research (NEC)

Hulsterweg 82
VENLO
LIMBURG 5912 PL
NL

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023